Vikas Lifecare Limited (VIKASLIFE) AI Stock Analysis

• Market Cap: ₹3.16B
• Dividend Yield: N/A
• Average Volume (3M): 850.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 9.42%
• EPS Growth: -12220.00%
• Country: IN
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals - Specialty
• EPS (TTM): N/A
• Shares Outstanding: 1,857,668,600
• 10 Day Avg. Volume: 448,294
• 30 Day Avg. Volume: 850,962
• PEG Ratio: 0.26
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -1.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ₹1.50 ▼(-16.67% Downside)

The overall stock score of 46 reflects significant financial challenges, including declining profitability and negative cash flows, which are the most impactful factors. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further limits positive influences on the score.

Positive Factors

Diversified distribution business model

An asset-light trading and distribution model across polymers and chemicals gives durable advantages: lower fixed costs, scalable logistics, and exposure to multiple end markets. This reduces single-sector dependency and supports steady order flows and resilience over the next several months.

Positive revenue growth trend

Reported ~9.4% revenue growth indicates demand resiliency or improved penetration in core product lines. Sustained top-line growth supports operating leverage opportunities and provides a foundation for margin recovery if cost and pricing discipline follow.

Relatively strong equity base with moderate leverage

A strong equity ratio and only moderate leverage provide a capital buffer for a distribution business with working-capital needs. This structural balance sheet strength affords flexibility to manage inventory and receivables during cyclical swings without immediate solvency risk.

Negative Factors

Declining profitability and negative margins

Persistent negative net margins and weakening EBIT/EBITDA indicate the core trading operations are not currently generating sustainable earnings. Without structural margin improvement via pricing, product mix, or cost control, profitability risks remain elevated for months ahead.

Negative operating cash flow and weak cash generation

Negative operating cash flow reflects inefficient working-capital management in a distribution model that relies on inventory and receivables. Continued cash outflows will necessitate external funding or tighter working-capital controls, limiting reinvestment and increasing liquidity risk.

Increased debt levels

Rising debt amplifies financial leverage at a time of negative earnings and cash flow, increasing interest burden and refinancing risk. For a trading business with variable margins, higher indebtedness reduces operational flexibility and raises vulnerability to demand shocks.

Vikas Lifecare Limited Business Overview & Revenue Model

Company Description

Vikas Lifecare Limited engages in the trading of various chemicals compounds, polymers, PVC resins, plastic granules, and products related to plastic industry in India. It operates through Real Estate, Trading- Polymers, Trading-Cashew Nuts, and Manufacturing divisions. The company is also involved in the real estate business; and the manufacture of recycled material for automotive, packaging, sheathing, and textile industries. In addition, it manufactures and sells polymer compounds, which include PE, PVC, V blend SOE, and polypropylene compounds, as well as thermo plastic rubber; deals in FMCG, cashew nuts, aluminum foils, and processed food products. Vikas Lifecare Limited also exports its products. The company was formerly known as Vikas Multicorp Limited and changed its name to Vikas Lifecare Limited in April 2021. Vikas Lifecare Limited was incorporated in 1995 and is based in New Delhi, India.

How the Company Makes Money

Vikas Lifecare Limited generates revenue primarily through the sale of its chemical products, including agrochemicals and polymer materials, to various industries such as agriculture, construction, and manufacturing. The company’s revenue model is built on both direct sales to customers and distribution agreements with key partners, expanding its reach in domestic and international markets. Additionally, Vikas Lifecare may benefit from strategic partnerships that allow for enhanced distribution capabilities and access to new customer segments, further contributing to its earnings. The company also explores opportunities in exporting its products, which can lead to increased revenue streams in foreign markets.

Vikas Lifecare Limited Financial Statement Overview

Summary

Vikas Lifecare Limited faces a challenging financial environment characterized by declining profitability, increased debt, and negative cash flows. While the company maintains a strong equity base, the operational performance needs significant improvement to enhance financial health and stability.

Income Statement

Vikas Lifecare Limited has shown volatile revenue growth with a notable decline in profitability. The gross profit margin is low, indicating cost pressures, and the net profit margin has deteriorated into negative territory, reflecting operational challenges. The EBIT and EBITDA margins have also weakened, contributing to financial instability.

Balance Sheet

The balance sheet demonstrates a moderate debt-to-equity ratio, suggesting a balanced approach to leveraging, though the debt has increased significantly over the year. The return on equity is negative due to net losses, but the equity ratio remains strong, indicating solid capital structure despite profitability challenges.

Cash Flow

Cash flow analysis reveals negative free cash flow growth and poor operating cash flow, indicating liquidity challenges. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. The company needs to improve cash generation to support its operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.80B	4.80B	4.46B	4.76B	3.01B	749.95M
Gross Profit	86.62M	38.79M	262.04M	243.20M	101.59M	112.35M
EBITDA	-16.41M	43.56M	240.93M	-160.98M	427.24M	43.39M
Net Income	-112.78M	-106.14M	140.29M	-152.99M	286.99M	-35.02M
Balance Sheet
Total Assets	0.00	7.29B	5.55B	4.55B	3.21B	1.49B
Cash, Cash Equivalents and Short-Term Investments	57.31M	431.74M	159.36M	113.13M	77.05M	1.88M
Total Debt	0.00	767.00M	344.90M	304.07M	230.77M	417.57M
Total Liabilities	-5.33B	1.96B	762.67M	1.21B	1.21B	822.82M
Stockholders Equity	5.33B	5.32B	4.77B	3.31B	1.99B	666.70M
Cash Flow
Free Cash Flow	0.00	-2.36B	-577.20M	-1.28B	-281.03M	-91.52M
Operating Cash Flow	0.00	-2.24B	-417.48M	-1.10B	-148.84M	-76.82M
Investing Cash Flow	0.00	1.03B	-906.01M	-366.38M	-385.14M	119.21M
Financing Cash Flow	0.00	1.12B	1.37B	1.51B	590.87M	-42.69M

Vikas Lifecare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIKASLIFE, the sentiment is Negative. The current price of 1.8 is above the 20-day moving average (MA) of 1.75, below the 50-day MA of 1.80, and below the 200-day MA of 2.24, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.46 is Neutral, neither overbought nor oversold. The STOCH value of 31.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIKASLIFE.

Vikas Lifecare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZIMLAB	63 Neutral	₹3.48B	52.76	―	―	-5.82%	-59.22%
MEDICAMEQ	57 Neutral	₹4.65B	41.80	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.95B	-26.19	―	0.66%	-13.51%	-122.00%
LYKALABS	51 Neutral	₹2.55B	-390.11	―	―	4.04%	-35.02%
VIKASLIFE	46 Neutral	₹3.16B	-28.05	―	―	9.42%	-12220.00%
NECLIFE	46 Neutral	₹3.01B	-0.85	―	―	-30.27%	-3470.06%